Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

genericon pharma gesellschaft m.b.h. - dimethylfumarat -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

genericon pharma gesellschaft m.b.h. - dimethylfumarat -

Europäische Union - Deutsch - EMA (European Medicines Agency)

almirall s.a - dimethylfumarat - psoriasis - immunsuppressiva - skilarence ist zur behandlung von mittelschwerer bis schwerer plaque-psoriasis bei erwachsenen indiziert, die eine systemische medikamentöse therapie benötigen.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

almirall ag - dimethylis fumaras - magensaftresistente tablette - dimethylis fumaras 30 mg, lactosum monohydricum 36 mg, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas, polysorbatum 80, talcum, triethylis citras, simeticonum, e 171, pro compresso obducto corresp. natrium 0.45 mg. - behandlung von hautmanifestationen bei patienten mit mittelschwerer bis schwerer plaque-psoriasis - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

almirall ag - dimethylis fumaras - magensaftresistente tablette - dimethylis fumaras 120 mg, lactosum monohydricum 144 mg, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas, polysorbatum 80, talcum, triethylis citras, simeticonum, e 132, e 171, natrii hydroxidum, pro compresso obducto corresp. natrium 1.94 mg. - behandlung von hautmanifestationen bei patienten mit mittelschwerer bis schwerer plaque-psoriasis - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

biogen netherlands b.v. - dimethylfumarat - multiple sklerose - immunsuppressiva - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - dimethylis fumaras - magensaftresistente hartkapseln - dimethylis fumaras 120 mg, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, talcum, silica colloidalis anhydrica, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, Überzug: acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum, polysorbatum 80, natrii laurilsulfas, triethylis citras, talcum, simeticonum, kapselhülle: gelatina, e 171, e 172 (flavum), e 133, drucktinte: lacca, kalii hydroxidum, e 172 (nigrum), pro capsula corresp. natrium 1.37 mg. - multiple sklerose - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - dimethylis fumaras - magensaftresistente hartkapseln - dimethylis fumaras 240 mg, carmellosum natricum conexum, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, Überzug: acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum, natrii laurilsulfas, triethylis citras, polysorbatum 80, talcum, simeticonum, kapselhülle: gelatina, e 171, e 172 (flavum), e 133, drucktinte: lacca, kalii hydroxidum, e 172 (nigrum), pro capsula corresp. natrium 1.69 mg. - multiple sklerose - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

mylan ireland limited - lenalidomid - multiples myelom - immunsuppressiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Europäische Union - Deutsch - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multiple sklerose, schubförmig-remittierender - immunsuppressiva - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).